In addition, a greater proportion of patients with median tumor expression of HER2 mRNA equal to or greater than the median versus below the median were from outside of the US (74.1% versus 63.8%), had ER-negative and/or PR-negative tumors (50.0% versus 34.5%), and equal to or fewer than two sites of disease involvement (47.4% versus 37.9%). The gene discussed is PGR; the disease is neoplasm.